Showing 4311-4320 of 8827 results for "".
- Study: Spironolactone May Be an Alternative to Antibiotics for Women With Persistent Acnehttps://practicaldermatology.com/news/study-spironolactone-may-be-an-alternative-to-antibiotics-for-women-with-persistent-acne/2461725/Spironolactone could be a cheap and readily available alternative to antibiotics for women with persistent acne, according to research out of the University of Southampton. The results of the trial appear in the Bri
- AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itchhttps://practicaldermatology.com/news/aobiomes-b244-eases-eczema-symptoms-helps-tame-itch/2461723/AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction The Phase 2b clinical data is published in
- More Phase 3 Data: Dermavant’s VTAMA Hits Primary and Secondary Endpoints for Kids and Adults with ADhttps://practicaldermatology.com/news/phase-3-data-dermavants-vtama-hits-primary-and-secondary-endpoints-for-kids-and-adults-with-ad/2461720/Dermavant Sciences’ VTAMA performed well in in adults and kids with atopic dermatitis, according to topline results from ADORING 1, the company’s second atopic dermatitis (AD) Phase 3 trial. VTAMA is a novel, aryl hydrocarbon receptor agonist, in development a
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Oral IL-23 Receptor Antagonist Makes Waves in Tokyohttps://practicaldermatology.com/news/oral-il-23-receptor-antagonist-makes-waves-in-tokyo/2461716/Protagonist Therapeutics and Janssen Biotech, Inc.'s oral IL-23 receptor antagonist, JNJ-2113, performed well in Phase 1 and Pre-clinical Studies. JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstr
- Rare Skin Disease Update: Abeona's EB-101 Performs Well in a Phase 3 study of RDEBhttps://practicaldermatology.com/news/rare-skin-disease-update-abeonas-eb-101-performs-well-in-a-phase-3-study-of-rdeb/2461715/Abeona Therapeutics Inc.’s investigational EB-101 performed well in a Phase 3 study of recessive dystrophic epidermolysis bullosa (RDEB). Both co-primary endpoints were met, with the majority (81.4%) of randomized EB-101–treated wounds demonstrating ≥50% healing compared
- Participating in an AD Trial: Weighing What Matters Most to Patients and Parentshttps://practicaldermatology.com/news/participating-in-an-ad-trial-weighing-what-matters-most-to-patients-and-parents/2461714/Key differences exist between what adults with eczema value for themselves in clinical trial participation versus what parents find important for their kids with this chronic skin disease, according to new research from the
- Mindfulness and Self-compassion Training Improve QOL for AD Patientshttps://practicaldermatology.com/news/mindfulness-and-self-compassion-training-improve-qol-for-ad-patients/2461713/Online group mindfulness and self-compassion training improves quality of life in adults with atopic dermatitis (AD). In this randomized clinical trial of 107 adults with AD, mindfulness and self-compassion training in addition to usual care showed significantly greater improvement
- Cutera Update: Agreements Made With Pura Vida and RTW; New Board Members Appointedhttps://practicaldermatology.com/news/cutera-update-agreements-made-with-pura-vida-and-rtw-new-board-members-appointed/2461712/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an